MX2022005633A - Novedosos agonistas del receptor tipo toll 9 (tlr9). - Google Patents

Novedosos agonistas del receptor tipo toll 9 (tlr9).

Info

Publication number
MX2022005633A
MX2022005633A MX2022005633A MX2022005633A MX2022005633A MX 2022005633 A MX2022005633 A MX 2022005633A MX 2022005633 A MX2022005633 A MX 2022005633A MX 2022005633 A MX2022005633 A MX 2022005633A MX 2022005633 A MX2022005633 A MX 2022005633A
Authority
MX
Mexico
Prior art keywords
novel
tlr9 agonists
oligonucleotides
tlr9
agonists
Prior art date
Application number
MX2022005633A
Other languages
English (en)
Spanish (es)
Inventor
Eiji Esashi
Original Assignee
Sbi Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sbi Biotech Co Ltd filed Critical Sbi Biotech Co Ltd
Publication of MX2022005633A publication Critical patent/MX2022005633A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2022005633A 2020-01-10 2021-01-08 Novedosos agonistas del receptor tipo toll 9 (tlr9). MX2022005633A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020002715 2020-01-10
PCT/JP2021/000543 WO2021141121A1 (en) 2020-01-10 2021-01-08 Novel tlr9 agonists

Publications (1)

Publication Number Publication Date
MX2022005633A true MX2022005633A (es) 2022-06-14

Family

ID=76787976

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005633A MX2022005633A (es) 2020-01-10 2021-01-08 Novedosos agonistas del receptor tipo toll 9 (tlr9).

Country Status (11)

Country Link
US (1) US20230323368A1 (OSRAM)
EP (1) EP4087931B1 (OSRAM)
JP (1) JP7750525B2 (OSRAM)
KR (1) KR20220125218A (OSRAM)
CN (1) CN114981436A (OSRAM)
AU (1) AU2021206355A1 (OSRAM)
BR (1) BR112022007935A2 (OSRAM)
CA (1) CA3161956A1 (OSRAM)
IL (1) IL294621A (OSRAM)
MX (1) MX2022005633A (OSRAM)
WO (1) WO2021141121A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4313315A4 (en) * 2021-04-01 2025-02-19 TriSalus Life Sciences, Inc. CANCER THERAPY USING TOLL-LIKE RECEPTOR AGONISTS
CN117568339A (zh) * 2023-01-19 2024-02-20 华普生物技术(河北)股份有限公司 CpG寡核苷酸及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
MX2010001785A (es) * 2007-08-15 2010-03-10 Idera Pharmaceuticals Inc Moduladores de receptores tipo larga distancia.
WO2010018583A1 (en) * 2008-08-14 2010-02-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Toll-like receptor 9 agonists for the treatment of anxiety-related disorders and inflammatory disorders
AU2010229835B2 (en) * 2009-03-25 2015-01-15 The Board Of Regents Of The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
WO2014201516A2 (en) * 2013-06-20 2014-12-24 Immunexpress Pty Ltd Biomarker identification
EP3892284B1 (en) * 2015-05-29 2024-05-22 Merck Sharp & Dohme LLC Combination of a pd-1 antagonist and a cpg-c type oligonucleotide for treating cancer
CN109475612A (zh) * 2016-04-15 2019-03-15 戴纳瓦克斯技术公司 肿瘤内给予含有Toll样受体9激动剂和肿瘤抗原的颗粒用于治疗癌症
JP7145853B2 (ja) * 2016-11-09 2022-10-03 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 適応免疫調節のための方法および組成物

Also Published As

Publication number Publication date
IL294621A (en) 2022-09-01
US20230323368A1 (en) 2023-10-12
KR20220125218A (ko) 2022-09-14
JP2023510491A (ja) 2023-03-14
CA3161956A1 (en) 2021-07-15
BR112022007935A2 (pt) 2022-07-12
AU2021206355A1 (en) 2022-07-07
EP4087931B1 (en) 2024-12-25
CN114981436A (zh) 2022-08-30
JP7750525B2 (ja) 2025-10-07
EP4087931A1 (en) 2022-11-16
WO2021141121A1 (en) 2021-07-15
EP4087931A4 (en) 2024-01-24

Similar Documents

Publication Publication Date Title
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
PH12020551261A1 (en) Il-15 conjugates and uses thereof
MX2024006824A (es) Degradadores de la proteina transductora de se?al y activadora de la transcripcion 3 (stat3) y usos de los mismos.
MX2025006196A (es) Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso
PH12020550936A1 (en) Combination drug including tlr7 agonist
GEAP202215447A (en) Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases
PH12020551144A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2020009942A (es) Compuestos y usos de los mismos.
WO2019209962A8 (en) Compounds and uses thereof
MX2019008124A (es) Metodos para el tratamiento de trastornos neurologicos.
BR112016006851A2 (pt) método de seleção de um agente para prevenção ou tratamento da esclerose lateral amiotrófica (ela), método de tratamento ou prevenção da progressão da ela em um indivíduo em mecessidade deste e uso de uma população celular de astrócitos progenitores humanos ou astrócitos
WO2019209948A8 (en) Compounds and uses thereof
MX2025012181A (es) Formas cristalinas de inhibidores de ras, composiciones que las contienen y metodos para su uso
PH12022552267A1 (en) Tie2-binding agents and methods of use
MX2021004755A (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria.
ZA202108579B (en) Inhibitors of notch signalling pathway and use thereof in treatment of cancers
PH12022551377A1 (en) Vegf mini-traps and method of use thereof
MX2020001632A (es) Composiciones que comprenden cepas bacterianas.
MX2024002069A (es) Anticuerpos anti-hla-g.
GEP20125432B (en) Improved testosterone gel and use thereof
AU201714195S (en) Industrial vehicle arm pad
MX2020004058A (es) Inhibidores de d-aminoacido oxidasa y sus usos terapeuticos.
MY194272A (en) Anti-msln antibody and pharmaceutical composition for cancer treatment comprising same
MX2024012565A (es) Composiciones farmaceuticas de mosunetuzumab y metodos de uso
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.